Skip to main content
Top

03-06-2024 | NSCLC | News

ASCO 2024

LAURA heralds practice change for locally advanced EGFR-mutated NSCLC

Author: Dr. Shreeya Nanda

medwireNews: Patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) could benefit from the use of osimertinib after chemoradiotherapy, suggest phase 3 trial data.

Related topics